Could this be the return of successful antibody treatment for Alzheimer's? Sevigny et al. at Biogen have shown that aducanumab has the potential to reduce characteristic Aβ plaques commonly associated with Alzheimer's pathology. https://t.co/Z0OJxnpkgb htt
‘The antibody aducanumab reduces Aβ plaques in #Alzheimer's disease.’ a @DovePress article on #ScienceOpen: https://t.co/zBewbSOYvH #WorldAlzheimersDay
@amitvkhera @psychgenomics Aducanumab (antibody against AB) first AD drug to show (highly significant) effect on plaques on PET and had nominal effect on MMSE in phase 2 of prodromal to mild AD (https://t.co/L7OFn0yBEn): results from phase 3 in 2019
The academic journal article that the about article was based on...https://t.co/erNJqgINrp. My cousin Robert Scannevin, is one of the authors!
@jordixiol @Dereklowe @MaverickNY @WilliamGerber1 More info on Aducanumab: https://t.co/XwUXpLNm0q
@Shaleo24 shush, here it is : https://t.co/wSqcgnEm7R THANK YOU LOOOOVE !
With aducanumab in the news, a look back at the paper in Nature: https://t.co/zTCtRES8zq $BIIB https://t.co/ihG2LB9jVy
RT @OrenoSource: 臨床試験薬、アルツハイマー病に「目覚ましい」効果 AFP https://t.co/y67KRfjuVF アミロイドβに対する抗体薬aducanumabの投与によりアミロイド斑が除去されたという臨床試験結果（nature）→ https:/…
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/FE5w2mtFhx
The amyloid hypothesis: Aβ plaques shrink & cognitive function improves with aducanumab in AD https://t.co/0KdJJztga3
Synaptic dysfunction https://t.co/1yJngfFw7w #HelterSkelterChallenge
Aducanumab the way to go for the treatment of Alzheimer's diseases? #dementia https://t.co/ZSuzvMT3i7
The hype has died down, but I'm hopeful for positive #aducanumab PhIII data in 2020. #Alzheimers https://t.co/OsJlLrJTYW https://t.co/gpTuYnQ1ft
REMARKABLE! Hope it works!!! https://t.co/GSkkohkXJN
Exciting news - potential drug to slow progression of Alzheimer's dementia. https://t.co/ipyn3PNQye
Alzheimer’s disease: deposits of Aβ plaques, neurofibrillary tangles, synaptic dysfunction & neurodegeneration https://t.co/o5YpvP3AYa
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/ayUA9IBXcH
The antibody aducanumab reduces Aβ plaques in #Alzheimer’s disease (from Sept 2016) https://t.co/SH6RTw2IGN
Good catch @NathanStall. Table 2 in fact indicates 2 in the placebo group had ARIA (contrary to the text) https://t.co/GlzEjer6sY #GeriMedJC
Fig 2c: change from baseline MMSE in aducanumab-treated patients https://t.co/G1tIldVqVZ #GeriMedJC https://t.co/Rhp5JILn84
Fig 2c: change from baseline CDR-SB in aducanumab-treated patients https://t.co/G1tIled2kz #GeriMedJC https://t.co/gv2FmagJMc
Fig 2a: amyloid plaque reduction, SUVR values https://t.co/G1tIldVqVZ #GeriMedJC https://t.co/DIWB2UzVPG
Table 2: most common adverse effects were amyloid-related imaging abnormalities, headache, UTI, URTI https://t.co/G1tIled2kz #GeriMedJC https://t.co/nnZYxDtEGS
Figure 1: Treatment reduced brain Aβ plaques in a dose- and time-dependent fashion. https://t.co/G1tIled2kz #GeriMedJC https://t.co/n1OVWzbBQj
Clinical assessments were exploratory as the study was not powered to detect clinical change. https://t.co/G1tIldVqVZ #GeriMedJC
Sensitivity analyses done using a mixed model for repeated measures. https://t.co/G1tIldVqVZ #GeriMedJC
Nominal P values presented with no adjustments for multiple comparisons. https://t.co/G1tIldVqVZ #GeriMedJC
Primary analyses based on observed data with no imputation for missing values. Fair? https://t.co/G1tIldVqVZ #GeriMedJC
Table 1. Baseline characteristics. Like your patients? https://t.co/G1tIled2kz #GeriMedJC https://t.co/iYLKpP8Opt
N = 165. Of these patients, 125 completed and 40 discontinued treatment https://t.co/G1tIldVqVZ #GeriMedJC
Intervention: IV aducanumab (1, 3, 6, or 10 mg/kg) or placebo once every 4 weeks for 52 weeks https://t.co/G1tIldVqVZ #GeriMedJC
Inclusion criteria: 50–90 years old and meeting clinical criteria for either prodromal or mild AD https://t.co/G1tIldVqVZ #GeriMedJC
Study design: multicentre, randomized, 12-month, double-blind, placebo-controlled, multiple-dose https://t.co/G1tIled2kz #GeriMedJC
Objective: evaluate safety and tolerability of aducanumab in prodromal AD or mild AD #dementia https://t.co/G1tIled2kz #GeriMedJC
.@NathanStall starts #GeriMedJC discussion with study of interim results of aducanumab trial for Alzheimer's disease https://t.co/XMDZjDE91N
Need links to the article for #GeriMedJC? Starts in 5 mins! https://t.co/XMDZjDE91N https://t.co/LXNufPoBqf
Source: https://t.co/wZBV6W1YkE (h/t >> https://t.co/57zsviQgOu) https://t.co/yDMkbX8ap5
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
RT @ibrahimimam2000: Aducanumab reduces Aβ plaques in #AlzheimersDisease https://t.co/0poSjfnFsm
Aducanumab reduces Aβ plaques in #AlzheimersDisease https://t.co/0poSjfnFsm
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
L'anticós aducanumab redueix les plaques Aβ en la malaltia d'Alzheimer. https://t.co/l2SLw79Bfw https://t.co/SiU3WKr70w
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Jeff Sevigny, Ping Chiao, Thierry Bussière,... https://t.co/bjeufJpiz2
RT @FutureofHealth: #Alzheimer #AlzheimersAwareness antibody aducanumab https://t.co/Nvg3N7S6KG
#Alzheimer #AlzheimersAwareness antibody aducanumab https://t.co/Nvg3N7S6KG
RT @MMUNeuroscience: Hard not to get excited about the latest results using #aducanumab in #Alzheimers patients! Excited for Phase 3. https…
RT @cynthiaermshar: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/by0CdIPjaR #EndAlz #FindACure https://t.…
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/by0CdIPjaR #EndAlz #FindACure https://t.co/FLjSBqYJ1Y
RT @Hesso_F_Sci: aducanumab, which selecively bind aggergated amyloid beta was claimed to work. https://t.co/qNqXWGNPo4 https://t.co/nDmVeB…
aducanumab, which selecively bind aggergated amyloid beta was claimed to work. https://t.co/qNqXWGNPo4 https://t.co/nDmVeB3vql
Aducanumab reduces amyloid Aß- plaques in (early stage) Alzheimer´s Disease according (small) phase 1B- study https://t.co/1cl4Aa8rTA
"The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease" (Nature 537 (2016) 50-56) https://t.co/jZaYQ1jN2R 抗体医薬の件、こちらも現代化学12月号から。
RT @NicholasCT: Rise of the biologics. https://t.co/8WMH82giUd
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/wvwtvCyqe0
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/Tl4wwUSsP3
Glimmer of hope? https://t.co/Z9j2CJs5Vl
Article 1: aducanumab for Alzheimer's dementia #geriupdate16 @dellightd https://t.co/motuiwGfIX https://t.co/WdD2z9j5a7
Una nueva luz en la batalla frente a la enfermedad de Alzheimer: https://t.co/OwvDTTj1YN.
EVIDENCE: The antibody Aducanumab reduces amyloid plaques in Alzheimer's Disease. https://t.co/c9K44uVTDO @hthsci4bb3 #hittingtheheadlines
Hope. https://t.co/v1YD0WdWaI
The antibody #Aducanumab reduces Aβ plaques in #Alzheimers; needs confirmation from ongoing phase 3 clinical trial. https://t.co/is66xROPB6
The antibody #aducanumab reduces Aβ plaques in #Alzheimer's disease. https://t.co/4X9lMjnyTB
Resultados del ensayo preclínico fase Ib de aducanumab, vía de investigación esperanzadora contra el #Alzheimer https://t.co/PZ95LdCoK8
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzwNHn https://t.co/N7…
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzOoyV https://t.co/wd…
New #Drug Shows Promise In Small Trial For #Alzheimer’s #disease https://t.co/3AVD824IGH #health
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzOoyV https://t.co/wd…
Biogen creating some great buzz with aducanumab. Would be a great advance in Alzheimer's therapy if things hold true https://t.co/tA5zYskDZG
RT @AshwinVV: Attacking amyloid with aducanumab. There's hope for Alzheimer's yet https://t.co/DIZMGYU4ij @NatureMedicine https://t.co/eLOW…
@joseluis_pa un paper calentito sobre el aducanumab, la inmunoterapias avanzan...pero, falta mucho https://t.co/6psx16tm9k
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/OiZ0pzF8ah
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzwNHn https://t.co/N7…
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
Aducanumab positive Phase I-B results - optimistic, but remember why Phase III is gold-standard! https://t.co/3GRopgvs0J
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzwNHn https://t.co/N7…
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzwNHn https://t.co/N7…
New research on antibody: Could be massive #breakthrough for #Alzheimers Is a cure close?🤔 https://t.co/qAl1p8IRIT #medicine #health
RT @denaturant: アルツハイマー薬として、Ab凝集体をターゲットにした王道の抗体はあんがい難航しているけど、aducanumabが最初の薬になるのかな。 https://t.co/smSVjIpzX6
アルツハイマー薬として、Ab凝集体をターゲットにした王道の抗体はあんがい難航しているけど、aducanumabが最初の薬になるのかな。 https://t.co/smSVjIpzX6
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
And in case you missed it, there was that study exploring immunotherapy for Alzheimer's: https://t.co/KWuPkPxyEZ
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. - PubMed - NCBI https://t.co/vB46jA71p9
RT @PDP_UAB: Interesting publication on #Alzheimer research in @nature The antibody aducanumab reduces Aβ plaques https://t.co/yDHbO8MZ5R
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @PDP_UAB: Interesting publication on #Alzheimer research in @nature The antibody aducanumab reduces Aβ plaques https://t.co/yDHbO8MZ5R
RT @PDP_UAB: Interesting publication on #Alzheimer research in @nature The antibody aducanumab reduces Aβ plaques https://t.co/yDHbO8MZ5R
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzwNHn https://t.co/N7…
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi